On this page
The short answer. Big tech is weaker than the rest of the market this morning, a day before Nvidia’s first results since its chief executive resigned. Index funds that track the Nasdaq 100 and the S&P 500 hold these big tech companies, so a slide in them reaches savers who never picked a single stock.
On StockTitan’s pre-market movers list, the largest moves are in drug developers, led by Summit Therapeutics, down 18.45%. A day earlier, Summit said the FDA cannot approve its application for ivonescimab with chemotherapy, in a form of lung cancer, in its present form. The table below gives each mover’s latest company news, small companies included.
The market before the bell, Monday
Every company reporting the same week, with its date and time, is in StockTitan's Earnings Calendar for the Week of November 16, 2026.
Live updates
The newest update comes first, each with the time it was written. Stock moves come from StockTitan’s real-time data unless another source is named.
6:45 a.m. ET
Tech stocks slip before the open, with Nvidia’s results a day away
The week starts with big tech under pressure. Nasdaq 100 futures were down 0.79%, a bigger drop than S&P 500 futures, while Dow futures edged up, according to CNBC’s live page, updated at 6:07 a.m. ET. In Asia, chip stocks such as Samsung, SK Hynix and TSMC fell sharply, CNBC said.
SPY, the S&P 500 fund, was down 0.32% at 6:36 a.m. ET, and Nvidia was down 2.55% at 6:41 a.m. ET. Nvidia said on November 12 that Huang had resigned and that finance chief Colette Kress is interim CEO. Its results come on Tuesday, November 17, at about 4:20 p.m. ET (Nvidia release). StockTitan’s article on the CEO change covers Huang’s exit.
Drug developers with fresh news made the largest single moves on StockTitan’s pre-market movers list. Helus Pharma rose 15.45% by 6:40 a.m. ET, before a webcast at 8:00 a.m. ET where it plans to present the main results of a late-stage depression trial (Helus release). By 6:41 a.m. ET, Strategy, a company that holds bitcoin, was down more than 6%. The Coinbase exchange and IBIT, the iShares fund that holds bitcoin, were each down more than 6% too.
Biggest stock movers today and the news behind them
Four drug developers made the largest moves on StockTitan’s pre-market movers list, each within a day of news about its medicines. Nvidia and XPeng moved less, and each had its own news.
| Company | Move | Company news |
|---|---|---|
| Helus Pharma (HELP) | +15.45%, pre-market, 6:40 a.m. ET | It plans to present the main results of APPROACH, its late-stage trial of HLP003 in major depressive disorder, in a webcast at 8:00 a.m. ET today (release). |
| Alpha Tau Medical (DRTS) | +13.60%, pre-market, 6:37 a.m. ET | On Sunday it said all eight patients treated with its Alpha DaRT radiation therapy in a trial for recurring brain cancer were alive as of November 11 (release). |
| XPeng (XPEV) | +3.31%, pre-market, 6:31 a.m. ET | The Chinese carmaker reported third-quarter revenue of RMB24.28 billion (US$3.62 billion), up 19.1% from a year earlier, and expects 169,000 to 174,000 deliveries in the fourth quarter (release). |
| Nvidia (NVDA) | -2.55%, pre-market, 6:41 a.m. ET | It said on November 12 that Jensen Huang had resigned as chief executive, and it reports quarterly results on Tuesday, November 17, at about 4:20 p.m. ET (release). |
| Aclaris Therapeutics (ACRS) | -17.09%, pre-market, 6:34 a.m. ET | Its mid-stage trial of bosakitug in the skin disease atopic dermatitis did not meet its main goal or its secondary goals (release). |
| Summit Therapeutics (SMMT) | -18.45%, pre-market, 6:41 a.m. ET | The FDA issued a complete response letter, a rejection in its present form, for ivonescimab with chemotherapy in a form of lung cancer (release). |
Source: StockTitan real-time Nasdaq data, against each stock’s November 13 close in StockTitan’s daily prices; company releases linked in each row.
XPeng also posted a third-quarter net loss, wider than a year earlier. Its fourth-quarter delivery outlook would be a rise of about 45% to 50% from a year earlier, the company says (XPeng release).
Why are biotech stocks moving today?
Each of the four drug developers had news about its medicines within the past day. Two were setbacks, one was early data the company calls positive, and one is a trial readout due this morning.
Summit’s drug slowed the cancer but did not prove patients lived longer. Without a statistically significant gain in overall survival, substantial evidence that the drug works was “not established,” the FDA found, according to Summit. In its trial, ivonescimab with chemotherapy met its goal on how long patients lived without the cancer growing. Summit says survival showed a positive trend that fell short of statistical significance. Summit says its belief in the drug is unchanged and that it is testing it in other cancers (Summit release, 8-K).
Helus will present its depression trial results at 8:00 a.m. ET. The APPROACH trial enrolled 223 adults whose depression did not respond enough to their current antidepressant (Helus quarterly release). HLP003 has the FDA’s Breakthrough Therapy designation, which the FDA says is meant to speed the development and review of drugs for serious conditions when early clinical evidence suggests a substantial improvement (FDA). Helus ended September with $171.1 million in cash, it said in its quarterly results (Helus quarterly release).
Alpha Tau’s update came from a small early trial. Five of the six patients assessed so far had a complete response, with no measurable tumor left at the treated site. The company also says scans in some patients show tissue damage from radiation, and that in two of them it cannot yet tell that from tumor growth (Alpha Tau release). Aclaris says the atopic dermatitis result does not change its plans, which center on its other drugs. The same morning it said it had started a mid-stage trial of modzatinib in the inflammatory disease lichen planus (Aclaris release).
What to watch for the rest of the day
Calls and a webcast from XPeng, Helus and Alpha Tau and one factory survey come before the 9:30 a.m. ET open. Nvidia reports on Tuesday after the close.
The New York Fed’s Empire State Manufacturing Survey, a monthly reading of factory activity in New York State, is due at 8:30 a.m. ET. In October its main index rose to 25.5, its highest since December 2021, the New York Fed said (New York Fed).
What to watch
- Did Helus’s APPROACH trial meet its main goal: its results webcast at 8:00 a.m. ET today.
- Did New York factory activity keep growing in November: the Empire State survey at 8:30 a.m. ET today, on the New York Fed calendar.
- What Nvidia reports for the quarter: its results release on Tuesday, November 17, at about 4:20 p.m. ET, per its November 12 release.
Our numbers
These figures are our calculations from the sources linked in this article.
- Nvidia about 9% below its last close before Huang resigned: the $158.70 trade at 6:41 a.m. ET against the $173.73 close of Wednesday, November 11, in StockTitan’s daily prices; Nvidia announced the resignation before the open on November 12.
- Each pre-market move on this page: the last trade at the time shown against the stock’s or fund’s November 13 close in StockTitan’s daily prices.
Frequently asked questions
Before the open on November 16, 2026, tech stocks pointed lower while traders waited for Nvidia’s results on Tuesday, CNBC reported. QQQ, the Nasdaq 100 fund, was down 0.88% at 6:41 a.m. ET. On StockTitan’s pre-market movers list, drug developers made the largest moves, led by Summit Therapeutics and Helus Pharma.
Summit fell 18.45% before the bell by 6:41 a.m. ET on November 16, 2026. The drop came a day after Summit said the FDA had issued a complete response letter on its application for ivonescimab with chemotherapy in a form of lung cancer, meaning that application cannot be approved in its present form. The FDA said substantial evidence of effectiveness was not established without a statistically significant survival gain, according to Summit.
Helus rose 15.45% before the bell by 6:40 a.m. ET on November 16, 2026. The rise came before its 8:00 a.m. ET webcast, where it plans to present the main results of its late-stage APPROACH trial in depression; the results were not out at 6:40 a.m. ET.
Alpha Tau rose 13.60% before the bell by 6:37 a.m. ET on November 16, 2026. The rise came a day after it said all eight patients in its US trial for recurring brain cancer were alive as of November 11, with complete responses in five of six assessed.
Aclaris fell 17.09% before the bell by 6:34 a.m. ET on November 16, 2026. The drop came hours after it said its mid-stage trial of bosakitug in atopic dermatitis did not meet its main goal.
Nvidia fell 2.55% before the bell by 6:41 a.m. ET on November 16, 2026, in StockTitan’s real-time data, leaving it about 9% below its November 11 close, the last before it said Jensen Huang had resigned. It reports quarterly results on Tuesday, November 17, at about 4:20 p.m. ET.
Sources
- StockTitan Earnings Calendar, week of November 16, 2026
- StockTitan, Nvidia CEO change
- Summit Therapeutics ivonescimab BLA update
- Summit Therapeutics Form 8-K, November 16, 2026
- Helus Pharma APPROACH webcast notice
- Helus Pharma second quarter fiscal 2027 results
- Alpha Tau REGAIN interim results
- Aclaris ADMIRATION trial results
- Aclaris modzatinib Phase 2b trial start
- XPeng third quarter 2026 results
- Nvidia CEO transition
- FDA, Breakthrough Therapy
- New York Fed, Empire State Manufacturing Survey
- New York Fed, economic indicators calendar